

SuperScript™ III First-Strand Synthesis SuperMix for qRT-PCR

Cat. No. 11752-050
11752-250

Size: 50 reactions
250 reactions

Store at –20°C

Description

SuperScript™ III First-Strand Synthesis SuperMix for qRT-PCR provides the high-temperature capability of SuperScript™ III Reverse Transcriptase in an optimized SuperMix format for the synthesis of first-strand cDNA for use in real-time quantitative RT-PCR (qRT-PCR).

SuperScript™ III Reverse Transcriptase, included in the RT Enzyme Mix, is a version of M-MLV RT that has been engineered to reduce RNase H activity and provide increased thermal stability (1, 2). The enzyme can be used to synthesize cDNA at a temperature range of 42–60°C, providing increased specificity, higher yields of cDNA, and more full-length product than other reverse transcriptases. Because SuperScript™ III RT is not significantly inhibited by ribosomal and transfer RNA, it can be used to synthesize cDNA from total RNA.

RNaseOUT™ Recombinant Ribonuclease Inhibitor, also included in the enzyme mix, is an RNase inhibitor protein that safeguards against the degradation of target RNA due to ribonuclease contamination of the RNA preparation.

The 2X RT Reaction Mix includes oligo(dT)₂₀, random hexamers, MgCl₂, and dNTPs in a buffer formulation that has been optimized for qRT-PCR.

E. coli RNase H is provided as a separate tube in the kit to remove the RNA template from the cDNA:RNA hybrid molecule after first-strand synthesis. This has been shown to increase sensitivity in qRT-PCR.

This SuperMix formulation can be used to quantify fewer than 10 copies of a target gene in qRT-PCR, with a broad dynamic range that supports accurate quantification of high-copy mRNA from up to 1 µg of total RNA. Reagents are provided for 50 or 250 RT reactions of 20 µl each.

Kit Components

<u>Component</u>	<u>50-rxn kit</u>	<u>250-rxn kit</u>
RT Enzyme Mix (includes SuperScript™ III RT and RNaseOUT™)	100 µl	500 µl
2X RT Reaction Mix (includes oligo(dT) ₂₀ (2.5 µM), random hexamers (2.5 ng/µl), 10 mM MgCl ₂ , and dNTPs)	500 µl	2 × 1.25 ml
<i>E. coli</i> RNase H	50 µl	250 µl

Two-Step qRT-PCR Kits

This kit is also included in the following two-step qRT-PCR kits:

- SuperScript™ Platinum® Two-Step qRT-PCR Kit with ROX, catalog nos. 11747-100 and 11747-500.
- SuperScript™ Platinum® SYBR® Green Two-Step qRT-PCR Kit with ROX, catalog nos. 11748-100 and 11748-500.
- SYBR® Greener™ Two-Step qRT-PCR Kit for ABI PRISM®, catalog nos. 11763-100 and 11763-500
- SYBR® Greener™ Two-Step qRT-PCR Kit for iCycler®, catalog nos. 11764-100 and 11764-500
- SYBR® Greener™ Two-Step qRT-PCR Kit, Universal, catalog nos. 11765-100 and 11765-500

Storage

Store components at –20°C. Stability can be extended by storing at –80°C.

RNA Guidelines

- High-quality, intact RNA is essential for full-length, high-quality cDNA synthesis and accurate mRNA quantification. Starting material can range up to 1 µg of total RNA.
- RNA should be devoid of any RNase contamination and aseptic conditions should be maintained. RNaseOUT™ is included in the RT Enzyme Mix to safeguard against degradation of target RNA due to ribonuclease contamination.
- To isolate total RNA, we recommend the PureLink™ Micro-to-Midi™ Total RNA Purification System, TRIzol® Reagent, or the PureLink™ 96 Total RNA Purification Kit for high-throughput applications (see **Additional Products** on page 3). Isolation of mRNA is typically not necessary, although incorporating this step may improve the yield of specific cDNAs.
- We recommend using DNase I, Amplification Grade, to eliminate genomic DNA contamination from the total RNA (see **Additional Products** on page 3).

Protocol for First-Strand cDNA Synthesis

The following protocol has been optimized for generating first-strand cDNA for use in two-step qRT-PCR. Note that an incubation temperature of 50°C for 30 minutes is recommended as a general starting point. Higher temperatures (up to 60°C) may be used for difficult templates.

1. Combine the following kit components in a tube on ice. For multiple reactions, a master mix without RNA may be prepared:

2X RT Reaction Mix	10 µl
RT Enzyme Mix	2 µl
RNA (up to 1 µg)	x µl
DEPC-treated water	to 20 µl

2. Gently mix tube contents and incubate at 25°C for 10 minutes.
3. Incubate tube at 50°C for 30 minutes.
4. Terminate the reaction at 85°C at 5 minutes, and then chill on ice.
5. Add 1 µl (2 U) of *E. coli* RNase H and incubate at 37°C for 20 minutes.
6. Use diluted or undiluted cDNA in qPCR, or store at –20°C until use.

Note: Up to 10% of the qPCR reaction volume may be undiluted cDNA (*e.g.*, for a 50-µl qPCR, use up to 5 µl of undiluted cDNA from Step 6 above).

Two-Step qRT-PCR Reactions

This kit is included with the two-step qRT-PCR kits listed on page 1. See the quick reference card provided with these kits, as well as the product documentation provided separately with the qPCR component of each kit, for qPCR guidelines and protocols.

This kit may also be used with stand-alone qPCR kits (see **Additional Products**, page 3).

Quality Control

The product was tested functionally in a two-step qRT-PCR procedure using total HeLa RNA as template. Kinetic analysis demonstrated a linear dose response with decreasing target concentration and detection of β-actin mRNA in 1 pg of total HeLa RNA.

Troubleshooting Guide

Use the following guide to identify and solve problems with the cDNA synthesis reaction in two-step qRT-PCR. Consult your qPCR manual for troubleshooting information on the qPCR component of the reaction.

Problem	Possible Cause	Probable Solution
No qRT-PCR amplification product Relative fluorescent signal \leq background or no template control	cDNA synthesis temperature too high, low priming efficiency RT or cDNA primer blocked by secondary structure RNA has been damaged or degraded RNase contamination	Lower incubation temperature. Raise incubation temperature. Redesign primer(s). Replace RNA if necessary. Maintain aseptic conditions; add RNase inhibitor.
Poor sensitivity	Not enough starting template RNA	Increase the concentration of template RNA; use up to 1 μ g of total RNA.
Product detected at higher than expected cycle number	RNA has been damaged or degraded RNase contamination RT inhibitors are present in RNA Inefficient cDNA synthesis	Replace RNA if necessary. Maintain aseptic conditions; add RNase inhibitor. Remove inhibitors in the RNA preparation by an additional 70% ethanol wash. Inhibitors of RT include SDS, EDTA, guanidium salts, formamide, sodium phosphate and spermidine. Adjust cDNA synthesis temperature.
Product detected at lower-than-expected cycle number, and/or positive signal from no-template controls	Template or carry-over contamination	Isolate source of contamination and replace reagent(s). Use separate dedicated pipettors for reaction assembly and post-qPCR analysis. Assemble reactions (except for target addition) in a DNA-free area. Use aerosol-resistant pipette tips or positive displacement pipettors.
	Too much sample added to reactions	Decrease the concentration of cDNA
Unexpected bands after electrophoresis	RNA contamination with genomic DNA	Pre-treat RNA with DNase I.

Additional Products

The following qPCR kits are compatible with this kit and are available separately from Invitrogen.

	<u>Amount</u>	<u>Cat. No.</u>
PureLink™ Micro-to-Midi Total RNA Purification System	50 rxns	12183-018
PureLink™ 96 Total RNA Purification Kit	384 rxns	12173-011
TRIzol® Reagent	100 ml 200 ml	15596-026 15596-018
Platinum® Quantitative PCR SuperMix-UDG	100 rxns 500 rxns	11730-017 11730-025
Platinum® Quantitative PCR SuperMix-UDG with ROX	100 rxns 500 rxns	11743-100 11743-500
SYBR Greener™ qPCR SuperMix, Universal	100 rxns 500 rxns	11762-100 11762-500
SYBR Greener™ qPCR SuperMix for ABI PRISM®	100 rxns 500 rxns	11760-100 11760-500
SYBR Greener™ qPCR SuperMix for iCycler®	100 rxns 500 rxns	11761-100 11761-500
DNase I, Amplification Grade	100 units	18068-015

References

1. Kotewicz, M.L., D'Alessio, J.M., Driftmier, K.M., Blodgett, K.P., and Gerard, G.F. (1985) Cloning and overexpression of Moloney murine leukemia virus reverse transcriptase in *Escherichia coli*. *Gene* 35, 249.
2. Gerard, G.F., D'Alessio, J.M., Kotewicz, M.L., and Noon, M.C. (1986) Influence on stability in *Escherichia coli* of the carboxy-terminal structure of cloned Moloney murine leukemia virus reverse transcriptase. *DNA* 5, 271.

Purchaser Notification

Limited Use Label License No. 4: Products for PCR which do not include any rights to perform PCR

This product is optimized for use in the Polymerase Chain Reaction (PCR) covered by patents owned by Roche Molecular Systems, Inc. and F. Hoffmann-La Roche, Ltd. ("Roche"). No license under these patents to use the PCR process is conveyed expressly or by implication to the purchaser by the purchase of this product. A license to use the PCR process for certain research and development activities accompanies the purchase of certain reagents from licensed suppliers such as Invitrogen, when used in conjunction with an Authorized Thermal Cycler, or is available from Applied Biosystems. Further information on purchasing licenses to practice the PCR process may be obtained by contacting the Director of Licensing at Applied Biosystems, 850 Lincoln Centre Drive, Foster City, California 94404 or at Roche Molecular Systems, Inc., 1145 Atlantic Avenue, Alameda, California 94501.

Limited Use Label License No. 5: Invitrogen Technology

The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Invitrogen Corporation will not assert a claim against the buyer of infringement of patents owned or controlled by Invitrogen Corporation which cover this product based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500. Email: outlicensing@invitrogen.com.

©2005–2006 Invitrogen Corporation. All rights reserved.

For research use only. Not intended for any animal or human therapeutic or diagnostic use.